ATE514090T1 - Verwendung des proteins satb2 als marker zur unterscheidung kolorektaler karzinome von anderen krebserkrankungen - Google Patents

Verwendung des proteins satb2 als marker zur unterscheidung kolorektaler karzinome von anderen krebserkrankungen

Info

Publication number
ATE514090T1
ATE514090T1 AT10158956T AT10158956T ATE514090T1 AT E514090 T1 ATE514090 T1 AT E514090T1 AT 10158956 T AT10158956 T AT 10158956T AT 10158956 T AT10158956 T AT 10158956T AT E514090 T1 ATE514090 T1 AT E514090T1
Authority
AT
Austria
Prior art keywords
marker
colorectal carcinoma
cancer diseases
differentiate
satb2
Prior art date
Application number
AT10158956T
Other languages
English (en)
Inventor
Mathias Uhlen
Fredrik Ponten
Original Assignee
Atlas Antibodies Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atlas Antibodies Ab filed Critical Atlas Antibodies Ab
Application granted granted Critical
Publication of ATE514090T1 publication Critical patent/ATE514090T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT10158956T 2006-06-02 2007-06-04 Verwendung des proteins satb2 als marker zur unterscheidung kolorektaler karzinome von anderen krebserkrankungen ATE514090T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06114954A EP1862803A1 (de) 2006-06-02 2006-06-02 Verwendung des Proteins SATB2 als Marker für kolorektale Karzinome
US81661306P 2006-06-27 2006-06-27

Publications (1)

Publication Number Publication Date
ATE514090T1 true ATE514090T1 (de) 2011-07-15

Family

ID=36968849

Family Applications (2)

Application Number Title Priority Date Filing Date
AT10158956T ATE514090T1 (de) 2006-06-02 2007-06-04 Verwendung des proteins satb2 als marker zur unterscheidung kolorektaler karzinome von anderen krebserkrankungen
AT07725799T ATE513216T1 (de) 2006-06-02 2007-06-04 Verwendung des proteins satb2 als prognostischer marker für kolorektalkarzinome

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07725799T ATE513216T1 (de) 2006-06-02 2007-06-04 Verwendung des proteins satb2 als prognostischer marker für kolorektalkarzinome

Country Status (11)

Country Link
US (3) US8067190B2 (de)
EP (3) EP1862803A1 (de)
JP (2) JP4990970B2 (de)
CN (2) CN101460850A (de)
AT (2) ATE514090T1 (de)
AU (1) AU2007256391B2 (de)
CA (1) CA2653952A1 (de)
DK (2) DK2024747T3 (de)
ES (1) ES2367412T3 (de)
PL (1) PL2211180T3 (de)
WO (1) WO2007140966A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100662821B1 (ko) * 2006-04-05 2006-12-28 유니트마 주식회사 레시피언트 블록 성형용 몰드 및 이를 이용한 레시피언트블록의 제조방법
EP1862803A1 (de) 2006-06-02 2007-12-05 Atlas Antibodies AB Verwendung des Proteins SATB2 als Marker für kolorektale Karzinome
EP2107375A1 (de) * 2008-03-31 2009-10-07 Atlas Antibodies AB Verwendungen von WARS-Protein bei der Krebsprognose
EP2172477A1 (de) 2008-10-06 2010-04-07 Atlas Antibodies AB Neue Epitope und Verwendungen davon
AU2009339802B2 (en) * 2009-02-16 2014-07-24 Atlas Antibodies Ab RBM3 as a marker for malignant melanoma prognosis
ES2709056T3 (es) * 2014-05-13 2019-04-15 Vastcon La sobreexpresión de la metionina aminopeptidasa en la sangre periférica y las células mononucleares de la sangre periférica son un marcador para la detección, el diagnóstico y el pronóstico del cáncer colorrectal
US11326210B2 (en) * 2015-01-30 2022-05-10 Glax Llc Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer
US20160258438A1 (en) * 2015-03-05 2016-09-08 Regal Beloit America, Inc. Assembly, blower and associated method
US20180282815A1 (en) * 2015-04-29 2018-10-04 Geneoscopy, Llc Colorectal cancer screening method and device
CA3077798A1 (en) 2016-10-27 2018-05-03 Geneoscopy, Llc Method of isolating eukaryotic nucleic acid from a stool sample
CN106841131A (zh) * 2016-12-29 2017-06-13 上海交通大学 一种基于角蛋白自荧光作为预测检测肿瘤的生物标志物的检测方法及其应用
CA3136405A1 (en) 2018-06-01 2019-12-05 Geneoscopy, Inc. Detection method for cancer using rna biomarkers
WO2020031206A1 (en) * 2018-08-08 2020-02-13 Indian Institute Of Science Education And Research Combined expression pattern of satb family chromatin organizers as improved biomarker tool for cancer prognosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828840D0 (en) 1998-12-30 1999-02-17 Univ Nottingham Trent Prostate cancer associated genes and their products
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
AU2002332606A1 (en) * 2001-08-21 2003-03-24 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20090215711A1 (en) * 2004-04-30 2009-08-27 Sagres Discovery, Inc. Novel compositions and methods in cancer
DE102004037860A1 (de) * 2004-08-04 2006-03-16 Friedrich-Alexander-Universität Erlangen-Nürnberg Turmormarker zur Diagnose von Karzinomen und/oder davon abstammender Metastasen
CN102191320A (zh) * 2005-05-02 2011-09-21 东丽株式会社 用于诊断食管癌的组合物及方法
GB2435882A (en) 2006-03-09 2007-09-12 Bioinvent Int Ab Detection and treatment of mantle cell lymphoma
EP1862803A1 (de) 2006-06-02 2007-12-05 Atlas Antibodies AB Verwendung des Proteins SATB2 als Marker für kolorektale Karzinome

Also Published As

Publication number Publication date
DK2211180T3 (da) 2011-09-26
JP2012073260A (ja) 2012-04-12
AU2007256391B2 (en) 2011-05-19
US8465934B2 (en) 2013-06-18
CN103293307B (zh) 2016-03-23
JP2009539082A (ja) 2009-11-12
EP2024747B1 (de) 2011-06-15
EP2211180B1 (de) 2011-06-22
JP4990970B2 (ja) 2012-08-01
US20090220975A1 (en) 2009-09-03
US8241859B2 (en) 2012-08-14
ES2367412T3 (es) 2011-11-03
US20120028836A1 (en) 2012-02-02
DK2024747T3 (da) 2011-09-19
EP1862803A1 (de) 2007-12-05
AU2007256391A1 (en) 2007-12-13
CN103293307A (zh) 2013-09-11
CA2653952A1 (en) 2007-12-13
EP2024747A1 (de) 2009-02-18
US8067190B2 (en) 2011-11-29
WO2007140966A1 (en) 2007-12-13
ATE513216T1 (de) 2011-07-15
US20120270956A1 (en) 2012-10-25
PL2211180T3 (pl) 2011-11-30
JP5301630B2 (ja) 2013-09-25
CN101460850A (zh) 2009-06-17
EP2211180A1 (de) 2010-07-28

Similar Documents

Publication Publication Date Title
ATE514090T1 (de) Verwendung des proteins satb2 als marker zur unterscheidung kolorektaler karzinome von anderen krebserkrankungen
WO2011119934A3 (en) Methods and materials for detecting colorectal neoplasm
ATE450547T1 (de) Eml4-alk-fusionsgen
ATE527385T1 (de) Mit tumoren assoziierte genetische variationen
WO2010045318A3 (en) Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
WO2006110581A3 (en) Cancer-related genes
GB0607943D0 (en) Biomarkers for chronic transplant dysfunction
HK1115636A1 (en) Use of cyfra 21-1 as a marker for colorectal cancer cyfra 21-1
HK1110936A1 (en) Method for detecting misfolded proteins and prions
ATE471512T1 (de) Verwendung des proteins s100a 12 als marker für kolorektalkarzinom
WO2012154567A3 (en) Human invasion signature for prognosis of metastatic risk
DE602007001103D1 (de) Verfahren zur identifizierung von lrrk2 interagierenden molekülen und zur reinigung von lrrk2
WO2010127417A3 (en) Hepatocellular carcinoma
CY1112553T1 (el) Ανοσοπροσδιορισμοι υψηλης ευαισθησιας και κιτια για τον προσδιορισμο πεπτιδιων και πρωτεϊνων βιολογικου ενδιαφεροντος
ATE462803T1 (de) Kit und verfahren zum nachweis von urothelkarzinom
WO2011008746A3 (en) Serum markers associated with early and other stages of breast cancer
WO2007112054A3 (en) Facilitation of translocation of molecules through the gastrointestinal tract
WO2006110587A3 (en) Ddr2 in cancer diagnosis, detection and treatment
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
ATE544070T1 (de) Verfahren zum nachweis von tumorspezifischen fusionsproteinen
DE602007008872D1 (de) Mikrowellengestützte deglycosylierung von proteinen zur molekulargewichtsbestimmung durch massenspektrometrie
HK1136873A1 (en) Use of nnmt as a marker for lung cancer
WO2007087263A3 (en) Human zip1, zinc and citrate for prostate cancer screening
WO2006079334A3 (de) Verfahren zu nachweis und quantifizierung von proteinen unter verwendung von farbstoffen auf der basis von polymethinen
ATE412182T1 (de) Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties